DAF-2 Activators
DAF-2 Activators include a range of compounds that target various aspects of the insulin/IGF-1 signaling pathway, which DAF-2 is known to be a central part of. Compounds such as Insulin and IGF-1 directly bind and activate their respective receptors, setting off a cascade of downstream signaling events that enhance the activity of DAF-2. This activation is characterized by increased autophosphorylation of DAF-2, leading to heightened signal transduction. Other activators such as Genistein and LY294002, despite being inhibitors of certain signaling enzymes, can indirectly enhance DAF-2 activity through feedback mechanisms that compensate for their inhibitory effects, leading to receptor sensitization and subsequent enhanced signaling.
Further, compounds like Resveratrol, Metformin, Pioglitazone, and AICAR, act through various mechanisms to modulate the sensitivity and efficiency of insulin signaling. Resveratrol's activation of SIRT1 alters transcription factor activity, which in turn enhances DAF-2 activation. Metformin and AICAR's stimulation of AMPK improves the overall signaling efficacy of the insulin/IGF-1 pathway, thereby enhancing DAF-2 function. Pioglitazone, acting as a PPAR-γ agonist, increases sensitivity, amplifying DAF-2's response and IGF-1. Rapamycin, by inhibitingmTOR, indirectly upregulates insulin signaling, which can lead to an increased functional activity of DAF-2. PPAR-delta agonists, which are not specified by a single chemical entity and thus lack a CAS number, enhance fatty acid metabolism that supports insulin sensitivity, benefiting DAF-2 activation. Methylene blue, through its influence on the electron transport chain, affects energy balance and can indirectly lead to the enhancement of DAF-2 activity. Lastly, Sodium fluoride acts on G-proteins that interface with insulin signaling, enhancing the activation of DAF-2 by influencing adenylate cyclase activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $153.00 $1224.00 $12239.00 | 82 | |
Insulin binds to the insulin receptor, which activates PI3K signaling. PI3K activation enhances PDK1 and Akt activity, leading to the phosphorylation and inhibition of FOXO. DAF-2, an insulin-like receptor, is positively regulated by this insulin signaling, enhancing its downstream signaling efficiency. | ||||||
IGF-1R Inhibitor, PPP | 477-47-4 | sc-204008A sc-204008 sc-204008B | 1 mg 10 mg 100 mg | $112.00 $199.00 $877.00 | 63 | |
IGF-1 binds to IGF-1 receptors, triggering a similar pathway as insulin, involving PI3K and Akt activation. This results in increased activity of DAF-2 by promoting its autophosphorylation and consequent signal transduction efficacy. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein, a tyrosine kinase inhibitor, can paradoxically enhance the activity of certain receptor tyrosine kinases, like DAF-2, through a feedback mechanism that compensates for its inhibitory effects. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor, which, through feedback mechanisms, can upregulate insulin/IGF-1 signaling, indirectly enhancing the activity of DAF-2 by promoting receptor sensitization and subsequent signaling. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $60.00 $185.00 $365.00 | 64 | |
Resveratrol activates SIRT1, which is known to deacetylate and alter the activity of transcription factors that are part of the insulin/IGF-1 signaling pathway, ultimately leading to the enhanced activation of DAF-2. | ||||||
1,1-Dimethylbiguanide, Hydrochloride | 1115-70-4 | sc-202000F sc-202000A sc-202000B sc-202000C sc-202000D sc-202000E sc-202000 | 10 mg 5 g 10 g 50 g 100 g 250 g 1 g | $20.00 $42.00 $62.00 $153.00 $255.00 $500.00 $30.00 | 37 | |
Metformin activates AMPK, which can modulate insulin signaling sensitivity, thereby enhancing the activation of DAF-2 through improved signaling dynamics at the receptor level. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $54.00 $123.00 | 13 | |
Pioglitazone, a PPAR-γ agonist, enhances insulin sensitivity and signaling, which can augment the activation of DAF-2 by amplifying the signal received from endogenous insulin and IGF-1. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $60.00 $270.00 $350.00 | 48 | |
AICAR activates AMPK, which, like metformin, enhances insulin signaling sensitivity, leading to improved functional efficiency of DAF-2. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which is part of the nutrient-sensing pathway overlapping with insulin signaling. Inhibition of mTOR can lead to feedback upregulation of insulin signaling, thereby enhancing DAF-2 activation. | ||||||
Methylene blue | 61-73-4 | sc-215381B sc-215381 sc-215381A | 25 g 100 g 500 g | $42.00 $102.00 $322.00 | 3 | |
Methylene blue acts on the electron transport chain, affecting cellular metabolism and energy balance. This can influence insulin signaling sensitivity, indirectly enhancing DAF-2 activation through altered cellular energy status. | ||||||